Regeneron Pharmaceuticals, Inc. filed a Form S-8 registration statement with the Securities and Exchange Commission on November 19, 2026, to register an additional 12,000,000 shares of common stock issuable under its Second Amended and Restated 2014 Long-Term Incentive Plan.
Key Highlights
- New shares registered: 12,000,000 shares of common stock, par value $0.001 per share, added under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan.
- Prior registrations: The new shares are in addition to 12,000,000 shares registered in 2014 (Reg. No. 333-196799), 4,485,333 shares registered in September 2014 (Reg. No. 333-198794), 12,000,000 shares registered in 2017 (Reg. No. 333-218669), and 12,000,000 shares registered in 2020 (Reg. No. 333-239209).
- Registrant status: Regeneron is classified as a large accelerated filer according to the filing.
- Signing officer: The registration statement was signed by Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer, on November 19, 2026.
- Incorporation by reference: The filing incorporates the contents of the four prior S-8 registration statements by reference, pursuant to General Instruction E to Form S-8.
Regeneron Adds 12 Million Shares to Its 2014 Long-Term Incentive Plan Registration
According to the filing, Regeneron Pharmaceuticals, Inc. submitted a Form S-8 registration statement on November 19, 2026, to register an additional 12,000,000 shares of its common stock, par value $0.001 per share, issuable under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. The company disclosed that the registration is submitted in accordance with General Instruction E to Form S-8, and that the contents of the prior registration statements are incorporated by reference and made part of the new filing, except as amended.
The filing identifies four prior S-8 registration statements covering the same plan and class of securities: 12,000,000 shares under Registration No. 333-196799 filed June 16, 2014 (as amended September 17, 2014); 4,485,333 shares under Registration No. 333-198794 filed September 17, 2014; 12,000,000 shares under Registration No. 333-218669 filed June 12, 2017; and 12,000,000 shares under Registration No. 333-239209 filed June 16, 2020. The current filing adds 12,000,000 shares on top of those previously registered amounts.
The registration statement was signed by Leonard S. Schleifer, M.D., Ph.D., in his capacity as Board co-Chair, President and Chief Executive Officer. Also signing were Christopher Fenimore as Executive Vice President, Finance and Chief Financial Officer, and Jason Pitofsky as Senior Vice President, Controller. Exhibits filed include a legal opinion from Skadden, Arps, Slate, Meagher and Flom LLP and a consent from PricewaterhouseCoopers LLP. The company's principal executive offices are listed at 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707.
What Was Disclosed
Regeneron Pharmaceuticals filed a Form S-8 on November 19, 2026, to register 12,000,000 additional shares of common stock under its Second Amended and Restated 2014 Long-Term Incentive Plan, supplementing shares registered under four prior S-8 filings dating back to 2014.



Please wait processing your request...